Sigyn Therapeutics (SIGY) Price & Analysis

Compare

12 Followers

SIGY Stock Chart & Stats

$0.05

$0.00(0.00%)

At close: Dec 17 4:00 PM EST

$0.05

$0.00(0.00%)

Day’s Range― - ―

52-Week Range$0.04 - $5.00

Previous CloseN/A

Volume87.00

Average Volume (3M)1.22K

Market Cap

$80.27K

Enterprise Value$2.81M

Total Cash (Recent Filing)$85.57K

Total Debt (Recent Filing)$2.81M

Price to Earnings (P/E)―

Beta0.62

Next EarningsN/A

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-3.20

Shares Outstanding1,605,377

10 Day Avg. Volume2,995

30 Day Avg. Volume1,222

Financial Highlights & Ratios

PEG Ratio0.04

Price to Book (P/B)-0.94

Price to Sales (P/S)0.00

P/FCF Ratio-4.81

Enterprise Value/Market Cap34.99

Enterprise Value/Revenue486.47

Enterprise Value/Gross Profit972.93

Enterprise Value/Ebitda-1.40

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-2.8

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Innovative TechnologyThe company's proprietary blood purification technology addresses critical medical needs, offering potential for strong market demand and strategic partnerships in healthcare.

Strategic PartnershipsEngaging in strategic partnerships can enhance technology distribution and application, driving long-term growth and market penetration in the healthcare sector.

Research Funding OpportunitiesAccess to research funding and government contracts can accelerate development and deployment of medical solutions, supporting innovation and financial sustainability.

Bears Say

Financial InstabilityPersistent financial difficulties indicate challenges in achieving profitability and sustainability, posing risks to long-term operational viability and investor confidence.

Negative Cash FlowNegative cash flow from operations suggests poor efficiency and high cash burn, necessitating reliance on external funding and impacting financial health.

Lack Of Revenue GrowthThe absence of revenue growth highlights challenges in market competitiveness and operational performance, limiting the company's ability to scale and generate profits.

Sigyn Therapeutics News

Sigyn Therapeutics Secures Funding via New Convertible Notes

Sigyn Therapeutics ( ($SIGY) ) has issued an update. On February 6 and February 12, 2026, Sigyn Therapeutics,...

10d ago

SIGY

Sigyn Therapeutics Secures Convertible Note Agreement

Sigyn Therapeutics ( ($SIGY) ) has issued an update. On August 8, 2025, Sigyn Therapeutics, Inc. entered into...

7M ago

SIGY

Sigyn Therapeutics Delays 10-Q Filing

Sigyn Therapeutics ( ($SIGY) ) has released a notification of late filing. Sigyn Therapeutics, Inc. has announced a...

7M ago

SIGY

Sigyn Therapeutics Delays Q1 2025 10-Q Filing

Sigyn Therapeutics ( ($SIGY) ) has released a notification of late filing. Sigyn Therapeutics, Inc. has filed a...

10M ago

SIGY

Sigyn Therapeutics Delays Yearly Report Filing

Sigyn Therapeutics ( ($SIGY) ) has released a notification of late filing. Sigyn Therapeutics, Inc. has announced a...

11M ago

SIGY

Sigyn Therapeutics Strengthens Board with New Appointment

Sigyn Therapeutics ( ($SIGY) ) has provided an update. On January 11, 2025, Sigyn Therapeutics appointed Michael Ryan...

1y ago

SIGY

Sigyn Therapeutics Announces 1-for-40 Reverse Stock Split

Sigyn Therapeutics (SIGY) has released an update. Sigyn Therapeutics, Inc. announced a 1-for-40 reverse stock split effective January...

2y ago

SIGY

Sigyn Therapeutics announces 1-for-40 reverse stock split

Sigyn Therapeutics announced that a 1-for-40 reverse split of its common stock will be implemented tomorrow, January 31,...

2y ago

SIGY

Sigyn Therapeutics releases letter to shareholders

Sigyn Therapeutics announced the release of a shareholder letter authored by Chairman and Chief Executive Officer, Jim Joyce....

2y ago

SIGY

Sigyn Therapeutics appoints Jerry DeCiccio as CFO

Sigyn Therapeutics announced the appointment of Jerry DeCiccio, CPA, MBA, as CFO. Previously, he was CFO/COO at Intech...

2y ago

SIGY

Sigyn Therapeutics reports PCT patent submission to enhance chemo delivery

Sigyn Therapeutics disclosed the submission of a Patent Cooperation Treaty application entitled: “SYSTEM AND METHODS TO ENHANCE CHEMOTHERAPY...

2y ago

SIGY

EmergingGrowth.com to host a virtual conference

Emerging Growth Virtual Conference to be held on August 9-10. Webcast Link Published first on TheFly – the...

3y ago

ASPI

DRTS

EmergingGrowth.com to host a virtual conference

Emerging Growth Virtual Conference to be held on August 9-10. Webcast Link Published first on TheFly – the...

3y ago

ASPI

DRTS

Sigyn Therapeutics announces appointment of Marleau as Chief Scientific Officer

Sigyn Therapeutics announces the appointment of Annette Marleau, Ph.D. as Chief Scientific Officer, CSO, effective immediately. Dr. Marleau...

3y ago

SIGY

SIGY FAQ

What was Sigyn Therapeutics’s price range in the past 12 months?

Sigyn Therapeutics lowest stock price was $0.04 and its highest was $5.00 in the past 12 months.

What is Sigyn Therapeutics’s market cap?

Sigyn Therapeutics’s market cap is $80.27K.

When is Sigyn Therapeutics’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were Sigyn Therapeutics’s earnings last quarter?

Currently, no data Available

Is Sigyn Therapeutics overvalued?

According to Wall Street analysts Sigyn Therapeutics’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Sigyn Therapeutics pay dividends?

Sigyn Therapeutics does not currently pay dividends.

What is Sigyn Therapeutics’s EPS estimate?

Sigyn Therapeutics’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Sigyn Therapeutics have?

Sigyn Therapeutics has 1,605,377 shares outstanding.

What happened to Sigyn Therapeutics’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Sigyn Therapeutics?

Currently, no hedge funds are holding shares in SIGY

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Sigyn Therapeutics

Sigyn Therapeutics, Inc. operates as a development-stage therapeutic technology company. It offers Sigyn Therapy, a blood purification technology to overcome the limitations of previous drugs and devices to treat life-threatening inflammatory disorders, including sepsis, the cause of hospital deaths. The company also engages in evaluating the Sigyn Therapy to address various therapeutic targets, including endotoxin; peptidoglycan and lipoteichoic acid; viral pathogens; hepatic toxins; CytoVesicles; and tumor necrosis factor alpha, interleukin-1 beta, and interleukin 6, which are pro-inflammatory cytokines. The company is headquartered in San Diego, California.